Antiplatelet  ||| S:0 E:13 ||| NNP
Therapy  ||| S:13 E:21 ||| NNP
in  ||| S:21 E:24 ||| IN
Carotid  ||| S:24 E:32 ||| NNP
Artery  ||| S:32 E:39 ||| NNP
Stenting  ||| S:39 E:48 ||| NNP
and  ||| S:48 E:52 ||| CC
Carotid  ||| S:52 E:60 ||| NNP
Endarterectomy  ||| S:60 E:75 ||| NNP
in  ||| S:75 E:78 ||| IN
the  ||| S:78 E:82 ||| DT
Asymptomatic  ||| S:82 E:95 ||| NNP
Carotid  ||| S:95 E:103 ||| NNP
Surgery  ||| S:103 E:111 ||| NNP
Trial-2  ||| S:111 E:119 ||| NNP
Strokes  ||| S:119 E:127 ||| NNS
are  ||| S:127 E:131 ||| VBP
infrequent  ||| S:131 E:142 ||| JJ
but  ||| S:142 E:146 ||| CC
potentially  ||| S:146 E:158 ||| RB
serious  ||| S:158 E:166 ||| JJ
complications  ||| S:166 E:180 ||| NNS
following  ||| S:180 E:190 ||| VBG
carotid  ||| S:190 E:198 ||| JJ
intervention ||| S:198 E:210 ||| NN
,  ||| S:210 E:212 ||| ,
but  ||| S:212 E:216 ||| CC
antiplatelet  ||| S:216 E:229 ||| JJ
therapy  ||| S:229 E:237 ||| NN
can  ||| S:237 E:241 ||| MD
reduce  ||| S:241 E:248 ||| VB
these  ||| S:248 E:254 ||| DT
risks ||| S:254 E:259 ||| NNS
.  ||| S:259 E:261 ||| .
There  ||| S:261 E:267 ||| EX
are  ||| S:267 E:271 ||| VBP
currently  ||| S:271 E:281 ||| RB
no  ||| S:281 E:284 ||| DT
specific  ||| S:284 E:293 ||| JJ
guidelines  ||| S:293 E:304 ||| NNS
on  ||| S:304 E:307 ||| IN
dose  ||| S:307 E:312 ||| NN
or  ||| S:312 E:315 ||| CC
duration  ||| S:315 E:324 ||| NN
of  ||| S:324 E:327 ||| IN
peri-procedural  ||| S:327 E:343 ||| JJ
antiplatelet  ||| S:343 E:356 ||| JJ
treatment  ||| S:356 E:366 ||| NN
for  ||| S:366 E:370 ||| IN
patients  ||| S:370 E:379 ||| NNS
undergoing  ||| S:379 E:390 ||| VBG
carotid  ||| S:390 E:398 ||| JJ
intervention ||| S:398 E:410 ||| NN
.  ||| S:410 E:412 ||| .
Within  ||| S:412 E:419 ||| IN
the  ||| S:419 E:423 ||| DT
ongoing  ||| S:423 E:431 ||| JJ
Asymptomatic  ||| S:431 E:444 ||| NNP
Carotid  ||| S:444 E:452 ||| NNP
Surgery  ||| S:452 E:460 ||| NNP
Trial-2  ||| S:460 E:468 ||| NNP
( ||| S:468 E:469 ||| -LRB-
ACST-2 ||| S:469 E:475 ||| NNP
) ||| S:475 E:476 ||| -RRB-
,  ||| S:476 E:478 ||| ,
this  ||| S:478 E:483 ||| DT
study  ||| S:483 E:489 ||| NN
aimed  ||| S:489 E:495 ||| VBN
at  ||| S:495 E:498 ||| IN
assessing  ||| S:498 E:508 ||| VBG
the  ||| S:508 E:512 ||| DT
current  ||| S:512 E:520 ||| JJ
use  ||| S:520 E:524 ||| NN
of  ||| S:524 E:527 ||| IN
antiplatelet  ||| S:527 E:540 ||| JJ
therapy  ||| S:540 E:548 ||| NN
before ||| S:548 E:554 ||| RB
,  ||| S:554 E:556 ||| ,
during ||| S:556 E:562 ||| IN
,  ||| S:562 E:564 ||| ,
and  ||| S:564 E:568 ||| CC
after  ||| S:568 E:574 ||| IN
CEA  ||| S:574 E:578 ||| NNP
and  ||| S:578 E:582 ||| CC
CAS  ||| S:582 E:586 ||| NNP
in  ||| S:586 E:589 ||| IN
patients  ||| S:589 E:598 ||| NNS
with  ||| S:598 E:603 ||| IN
asymptomatic  ||| S:603 E:616 ||| JJ
carotid  ||| S:616 E:624 ||| JJ
stenosis ||| S:624 E:632 ||| NN
.  ||| S:632 E:634 ||| .
Questionnaires  ||| S:634 E:649 ||| NNP
were  ||| S:649 E:654 ||| VBD
sent  ||| S:654 E:659 ||| VBN
to  ||| S:659 E:662 ||| TO
ACST-2  ||| S:662 E:669 ||| CD
collaborators  ||| S:669 E:683 ||| NNS
seeking  ||| S:683 E:691 ||| VBG
information  ||| S:691 E:703 ||| NN
about  ||| S:703 E:709 ||| IN
the  ||| S:709 E:713 ||| DT
use  ||| S:713 E:717 ||| NN
of  ||| S:717 E:720 ||| IN
antiplatelet  ||| S:720 E:733 ||| JJ
therapy  ||| S:733 E:741 ||| NN
during  ||| S:741 E:748 ||| IN
the  ||| S:748 E:752 ||| DT
pre- ||| S:752 E:756 ||| JJ
,  ||| S:756 E:758 ||| ,
peri- ||| S:758 E:763 ||| NNP
,  ||| S:763 E:765 ||| ,
and  ||| S:765 E:769 ||| CC
post-operative  ||| S:769 E:784 ||| JJ
periods  ||| S:784 E:792 ||| NNS
in  ||| S:792 E:795 ||| IN
patients  ||| S:795 E:804 ||| NNS
undergoing  ||| S:804 E:815 ||| VBG
carotid  ||| S:815 E:823 ||| JJ
intervention  ||| S:823 E:836 ||| NN
at  ||| S:836 E:839 ||| IN
77  ||| S:839 E:842 ||| CD
participating  ||| S:842 E:856 ||| VBG
sites  ||| S:856 E:862 ||| NNS
and  ||| S:862 E:866 ||| CC
also  ||| S:866 E:871 ||| RB
whether  ||| S:871 E:879 ||| IN
sites  ||| S:879 E:885 ||| NNS
tested  ||| S:885 E:892 ||| VBN
for  ||| S:892 E:896 ||| IN
antiplatelet  ||| S:896 E:909 ||| JJ
therapy  ||| S:909 E:917 ||| NN
resistance ||| S:917 E:927 ||| NN
.  ||| S:927 E:929 ||| .
The  ||| S:929 E:933 ||| DT
response  ||| S:933 E:942 ||| NN
rate  ||| S:942 E:947 ||| NN
was  ||| S:947 E:951 ||| VBD
68 ||| S:951 E:953 ||| CD
/ ||| S:953 E:954 ||| CD
77  ||| S:954 E:957 ||| CD
( ||| S:957 E:958 ||| -LRB-
88 ||| S:958 E:960 ||| CD
% ||| S:960 E:961 ||| NN
) ||| S:961 E:962 ||| -RRB-
.  ||| S:962 E:964 ||| .
For  ||| S:964 E:968 ||| IN
CAS ||| S:968 E:971 ||| NNP
,  ||| S:971 E:973 ||| ,
82 ||| S:973 E:975 ||| CD
%  ||| S:975 E:977 ||| NN
of  ||| S:977 E:980 ||| IN
sites  ||| S:980 E:986 ||| NNS
used  ||| S:986 E:991 ||| VBN
dual  ||| S:991 E:996 ||| JJ
antiplatelet  ||| S:996 E:1009 ||| JJ
therapy  ||| S:1009 E:1017 ||| NN
( ||| S:1017 E:1018 ||| -LRB-
DAPT ||| S:1018 E:1022 ||| NNP
)  ||| S:1022 E:1024 ||| -RRB-
pre-operatively  ||| S:1024 E:1040 ||| JJ
and  ||| S:1040 E:1044 ||| CC
86 ||| S:1044 E:1046 ||| CD
%  ||| S:1046 E:1048 ||| NN
post-operatively  ||| S:1048 E:1065 ||| NN
with  ||| S:1065 E:1070 ||| IN
a  ||| S:1070 E:1072 ||| DT
mean  ||| S:1072 E:1077 ||| JJ
post-procedural  ||| S:1077 E:1093 ||| JJ
duration  ||| S:1093 E:1102 ||| NN
of  ||| S:1102 E:1105 ||| IN
3  ||| S:1105 E:1107 ||| CD
months  ||| S:1107 E:1114 ||| NNS
( ||| S:1114 E:1115 ||| -LRB-
range  ||| S:1115 E:1121 ||| NN
1-12 ||| S:1121 E:1125 ||| CD
) ||| S:1125 E:1126 ||| -RRB-
,  ||| S:1126 E:1128 ||| ,
while  ||| S:1128 E:1134 ||| IN
9 ||| S:1134 E:1135 ||| CD
%  ||| S:1135 E:1137 ||| NN
continued  ||| S:1137 E:1147 ||| VBD
DAPT  ||| S:1147 E:1152 ||| NNP
life-long ||| S:1152 E:1161 ||| NNP
.  ||| S:1161 E:1163 ||| .
For  ||| S:1163 E:1167 ||| IN
CEA  ||| S:1167 E:1171 ||| NNP
only  ||| S:1171 E:1176 ||| RB
31 ||| S:1176 E:1178 ||| CD
%  ||| S:1178 E:1180 ||| NN
used  ||| S:1180 E:1185 ||| VBD
DAPT  ||| S:1185 E:1190 ||| NNP
pre-operatively ||| S:1190 E:1205 ||| NNP
,  ||| S:1205 E:1207 ||| ,
24 ||| S:1207 E:1209 ||| CD
%  ||| S:1209 E:1211 ||| NN
post-operatively  ||| S:1211 E:1228 ||| NN
with  ||| S:1228 E:1233 ||| IN
a  ||| S:1233 E:1235 ||| DT
mean  ||| S:1235 E:1240 ||| JJ
post-procedural  ||| S:1240 E:1256 ||| JJ
duration  ||| S:1256 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
3  ||| S:1268 E:1270 ||| CD
months  ||| S:1270 E:1277 ||| NNS
( ||| S:1277 E:1278 ||| -LRB-
range  ||| S:1278 E:1284 ||| NN
1-5 ||| S:1284 E:1287 ||| CD
) ||| S:1287 E:1288 ||| -RRB-
,  ||| S:1288 E:1290 ||| ,
while  ||| S:1290 E:1296 ||| IN
10 ||| S:1296 E:1298 ||| CD
%  ||| S:1298 E:1300 ||| NN
continued  ||| S:1300 E:1310 ||| VBD
DAPT  ||| S:1310 E:1315 ||| NNP
life-long ||| S:1315 E:1324 ||| NNP
.  ||| S:1324 E:1326 ||| .
For  ||| S:1326 E:1330 ||| IN
those  ||| S:1330 E:1336 ||| DT
prescribing  ||| S:1336 E:1348 ||| FW
post-procedural  ||| S:1348 E:1364 ||| FW
mono  ||| S:1364 E:1369 ||| FW
antiplatelet  ||| S:1369 E:1382 ||| FW
( ||| S:1382 E:1383 ||| -LRB-
MAPT ||| S:1383 E:1387 ||| NNP
)  ||| S:1387 E:1389 ||| -RRB-
therapy  ||| S:1389 E:1397 ||| NN
( ||| S:1397 E:1398 ||| -LRB-
76 ||| S:1398 E:1400 ||| CD
% ||| S:1400 E:1401 ||| NN
) ||| S:1401 E:1402 ||| -RRB-
,  ||| S:1402 E:1404 ||| ,
aspirin  ||| S:1404 E:1412 ||| NN
was  ||| S:1412 E:1416 ||| VBD
more  ||| S:1416 E:1421 ||| RBR
commonly  ||| S:1421 E:1430 ||| RB
prescribed  ||| S:1430 E:1441 ||| VBN
( ||| S:1441 E:1442 ||| -LRB-
59 ||| S:1442 E:1444 ||| CD
% ||| S:1444 E:1445 ||| NN
)  ||| S:1445 E:1447 ||| -RRB-
than  ||| S:1447 E:1452 ||| IN
clopidogrel  ||| S:1452 E:1464 ||| NNS
( ||| S:1464 E:1465 ||| -LRB-
6 ||| S:1465 E:1466 ||| CD
% ||| S:1466 E:1467 ||| NN
)  ||| S:1467 E:1469 ||| -RRB-
and  ||| S:1469 E:1473 ||| CC
11 ||| S:1473 E:1475 ||| CD
%  ||| S:1475 E:1477 ||| NN
of  ||| S:1477 E:1480 ||| IN
centres  ||| S:1480 E:1488 ||| NN
did  ||| S:1488 E:1492 ||| VBD
not  ||| S:1492 E:1496 ||| RB
show  ||| S:1496 E:1501 ||| VB
a  ||| S:1501 E:1503 ||| DT
preference  ||| S:1503 E:1514 ||| NN
for  ||| S:1514 E:1518 ||| IN
either  ||| S:1518 E:1525 ||| DT
aspirin  ||| S:1525 E:1533 ||| NN
or  ||| S:1533 E:1536 ||| CC
clopidogrel ||| S:1536 E:1547 ||| NN
.  ||| S:1547 E:1549 ||| .
Eleven  ||| S:1549 E:1556 ||| JJ
centres  ||| S:1556 E:1564 ||| NNS
( ||| S:1564 E:1565 ||| -LRB-
16 ||| S:1565 E:1567 ||| CD
% ||| S:1567 E:1568 ||| NN
)  ||| S:1568 E:1570 ||| -RRB-
tested  ||| S:1570 E:1577 ||| VBN
for  ||| S:1577 E:1581 ||| IN
antiplatelet  ||| S:1581 E:1594 ||| JJ
therapy  ||| S:1594 E:1602 ||| NN
resistance ||| S:1602 E:1612 ||| NN
.  ||| S:1612 E:1614 ||| .
There  ||| S:1614 E:1620 ||| EX
appears  ||| S:1620 E:1628 ||| VBZ
to  ||| S:1628 E:1631 ||| TO
be  ||| S:1631 E:1634 ||| VB
broad  ||| S:1634 E:1640 ||| JJ
agreement  ||| S:1640 E:1650 ||| NN
on  ||| S:1650 E:1653 ||| IN
the  ||| S:1653 E:1657 ||| DT
use  ||| S:1657 E:1661 ||| NN
of  ||| S:1661 E:1664 ||| IN
antiplatelet  ||| S:1664 E:1677 ||| JJ
therapy  ||| S:1677 E:1685 ||| NN
in  ||| S:1685 E:1688 ||| IN
ACST-2  ||| S:1688 E:1695 ||| CD
patients  ||| S:1695 E:1704 ||| NNS
undergoing  ||| S:1704 E:1715 ||| VBG
carotid  ||| S:1715 E:1723 ||| JJ
artery  ||| S:1723 E:1730 ||| NN
stenting  ||| S:1730 E:1739 ||| NNS
and  ||| S:1739 E:1743 ||| CC
surgery ||| S:1743 E:1750 ||| NN
.  ||| S:1750 E:1752 ||| .
Although  ||| S:1752 E:1761 ||| IN
evidence  ||| S:1761 E:1770 ||| NN
to  ||| S:1770 E:1773 ||| TO
help  ||| S:1773 E:1778 ||| VB
guide  ||| S:1778 E:1784 ||| VB
the  ||| S:1784 E:1788 ||| DT
duration  ||| S:1788 E:1797 ||| NN
of  ||| S:1797 E:1800 ||| IN
peri-procedural  ||| S:1800 E:1816 ||| JJ
antiplatelet  ||| S:1816 E:1829 ||| JJ
therapy  ||| S:1829 E:1837 ||| NN
is  ||| S:1837 E:1840 ||| VBZ
limited ||| S:1840 E:1847 ||| VBN
,  ||| S:1847 E:1849 ||| ,
long-term  ||| S:1849 E:1859 ||| JJ
treatment  ||| S:1859 E:1869 ||| NN
with  ||| S:1869 E:1874 ||| IN
DAPT  ||| S:1874 E:1879 ||| NNP
appears  ||| S:1879 E:1887 ||| VBZ
similar  ||| S:1887 E:1895 ||| JJ
between  ||| S:1895 E:1903 ||| IN
both  ||| S:1903 E:1908 ||| DT
treatment  ||| S:1908 E:1918 ||| NN
arms ||| S:1918 E:1922 ||| NNS
.  ||| S:1922 E:1924 ||| .
